Higher mortality rate in Lung Cancer patients during COVID-19 pandemic

Dayyaneh feyzbakhsh, Ali Nemati Siyahmazgi, Hossein Javid ©

Higher mortality rate in Lung Cancer patients during COVID-19 pandemic

کد: G-82679

نویسندگان: Dayyaneh feyzbakhsh, Ali Nemati Siyahmazgi, Hossein Javid ©

زمان بندی: زمان بندی نشده!

برچسب: بیوشیمی

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by the severe acute respiratory syndrome (SARS-CoV-2). Lung cancer is the most common cancer among males with high mortality rate. lung cancer Patients may have severe COVID-19 complications. Optimal cancer care during COVID-19 pandemic could be designed if patient-specific and cancer-specific features which affect the severity of COVID 19 are better understood.




Reportedly, cancer patients have a higher risk of infection with SARS-CoV-2 (0.79%), in comparison with non-cancer patients (0.37%) because of their suppressed immune state caused by the malignancy and anticancer treatments. COVID-19 in lung cancer patients (7 out of 12) and patients aged 60 years or older was highly severe (62% hospitalized, 25% mortality). However, this severity only caused a small fraction of lung cancer deaths during pandemic (approximately 11%). COVID-19 severity factors to a large extent are related to patient-specific features such as smoking and chronic obstructive pulmonary disease. On the other hand, Cancer-specific features like prior thoracic surgery/radiation and systemic therapies did effect severity. Antigen supertypes of Human leukocyte were normally similar in mild or severe COVID-19 cases compared with non-COVID-19 controls. inflammatory monocyte and macrophage activation cause acute lung injury that results in release of proinflammatory cytokines such as interleukin (IL)-6, IL-1 and tumor necrosis factor-α which have vital role in immune-associated pneumonitis. Thus, these cytokines may be a therapeutic target when T cell is dominant in infiltration or there are signs of increased IL-6 inflammation as in increased C-reactive protein.


The mortality rate in lung cancer patients are higher than normal population. The high severity in lung cancer patients is linked with COVID-19 and features that are patient specific are the most determining factors of severity. A fairly good treatment option could be hydroxychloroquine combined with azithromycin. Of note, it is better to reduce hospital visits as they could increase the risk of nosocomial transmission


Lung Cancer; COVID-19; SARS-CoV-2

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.